How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01.

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA) , BHP Group (BHP) , Sorrento Therapeutics (SRNE) , OPKO Health (OPK) , Amarin (AMRN) , Matinas BioPharma (MTNB) , Micron Technology (MU) , Rite Aid (RAD) , VBI Vaccines (VBIV) and Acasti Pharma (ACST) .

When did Proteostasis Therapeutics IPO?

Proteostasis Therapeutics (PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

NASDAQ:PTI

Proteostasis Therapeutics (PTI) Stock Price, News & Analysis

→ The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad)

Free PTI Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.34
▼
$0.39
50-Day Range: $1.00
▼
$22.42
52-Week Range: $0.87
▼
$2.72

Volume: 164,078 shs
Average Volume: 1.04 million shs
Market Capitalization: $17.74 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Proteostasis Therapeutics alerts:

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Proteostasis Therapeutics Stock (NASDAQ:PTI)

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

Click here to download your report

PTI Stock News Headlines

July 20, 2023 | bizjournals.com

Greensboro joins incentive offers for $55M Honda expansion at PTI; Guilford County up next

March 13, 2023 | bloomberg.com

Federal Police Summons India Minister in Bribery Probe, PTI Says

April 15, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

October 6, 2022 | nj.com

7 years later, probation and PTI for pair in North Bergen low-show/no-show job scheme

October 26, 2021 | finance.yahoo.com

Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options

See More Headlines

Receive PTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteostasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/16/2020
Today: 4/15/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PTI
CUSIP: N/A
CIK: 1445283
Web: www.proteostasis.com
Phone: 617-225-0096
Fax: N/A
Employees: 44
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-59,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -75.39%
Return on Assets: -55.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.69
Quick Ratio: 6.69

Sales & Book Value

Annual Sales: $5 million
Price / Sales: 3.55
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.22 per share
Price / Book: 0.28

Miscellaneous

Outstanding Shares: 52,185,000
Free Float: N/A
Market Cap: $17.74 million
Optionable: Not Optionable
Beta: 1.16

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Ms. Meenu Chhabra (Age 48)
Pres, CEO & Director
Comp: $844.78k
Dr. Marija Zecevic (Age 46)
Chief Commercial Officer
Comp: $530.46k
Michael L. Alfieri
Head of Fin.
Dr. Benito Munoz (Age 58)
Chief Scientific Officer
Ms. Janet L. Smart Esq. (Age 63)
Ph.D., J.D., Sr. VP of Legal Affairs
Dr. Geoffrey S. Gilmartin (Age 52)
Chief Medical Officer
Ms. Claudia Styslinger
Investor Relations Exec.

Key Competitors

View All Competitors

PTI Stock Analysis - Frequently Asked Questions

How were Proteostasis Therapeutics' earnings last quarter?: Proteostasis Therapeutics, Inc. (NASDAQ:PTI) announced its quarterly earnings data on Monday, November, 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01.
What other stocks do shareholders of Proteostasis Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Amarin (AMRN), Matinas BioPharma (MTNB), Micron Technology (MU), Rite Aid (RAD), VBI Vaccines (VBIV) and Acasti Pharma (ACST).
When did Proteostasis Therapeutics IPO?: Proteostasis Therapeutics (PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

This page (NASDAQ:PTI) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Proteostasis Therapeutics (PTI) Stock Price, News & Analysis

About Proteostasis Therapeutics Stock (NASDAQ:PTI)

PTI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PTI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info